Author Archives: Matthew Raybould

OAS-nano: New Repertoire Database Just Dropped

Those familiar with the immunoinformatics work of our group will know of our Observed Antibody Space (OAS) and Observed T-cell Receptor Space (OTS) databases, which compile and consistently process V(D)J transcriptomics datasets from across a range of studies on natural immune repertoires. These have provided a central community resource of training data for adaptive immune receptor (AIR) large language models, as well as references for studies aiming to identify clones related to particular disease states.

We are now delighted to release the final installment of our natural AIR database series: introducing OAS-nano. This project was enabled by key collaborative contributions from Klara Kropivsek Brumat and Ario de Marco at the University of Nova Gorica and our industrial partners at AstraZeneca: Olga Obrezanova, Erwin de Genst, and Rebecca Croasdale-Wood.

Continue reading →

New DPhil/PhD Programme in Pharmaceutical Science Joint with GSK!

Many OPIGlets found their way into a DPhil in Protein Informatics through our Systems Approaches to Biomedical Sciences Industrial Doctoral Landscape Award, which was open to applicants 2009-2024. This innovative course, based at the MPLS Doctoral Training Centre (DTC), offered six months of intensive taught modules prior to starting PhD-level research, allowing students to upskill across a diverse range of subjects (coding, mathematics, structural biology, etc.) and to go on to do research in areas significantly distinct from their formal Undergraduate training. All projects also benefited from direct co-supervision from researchers working in the Pharmaceutical industry, ensuring DPhil projects in areas with drug discovery translation potential. Regrettably, having twice successfully applied for renewal of funding, we were unsuccessful in our bid to refund SABS in 2024.

Happily though, we can now formally announce that our bid for a direct successor to SABS, the Transformative Technologies in Pharmaceutical Sciences IDLA, has been backed by the BBSRC, and we will shortly be opening for applications for entry this October [2026]. As someone who benefited from the interdisciplinary training and industry-adjacency of SABS, I’m thrilled to be a co-director of this new Programme and to help deliver this course to a new generation of talented students.

Continue reading →

Nanobodies® galore in Utrecht

At the end of September, I had the opportunity to present at the 4th Single-Domain Antibody (sdAb/VHH) Conference hosted in the city of Utrecht. The sdAb conference is a biennial event, and was held for the first time in Bonn (2019), then in Brussels (2021) and Paris (2023), before coming to the Netherlands this year.

This was the first time I’d attended a VHH-focused conference, and I was taken aback at just how large the community is; the Jaarbeurs ‘Supernova’ event hall was completely sold out, with over 400 researchers in attendance (pictures below courtesy of the organisers). The buzz reflects the ever growing interest in sdAbs as tools to discover new fundamental biology, vectors for diagnosing disease, and as prophylactic or curative therapeutics. Most every disease indication was represented at the conference, from anticancer and antiviral sdAbs to antivenom sdAbs (both for use in lateral flow tests to diagnose the snake that bit you, and as quick ‘epipen’-like therapeutics accessible even in the most remote parts of the world).

Continue reading →

A Masterclass in Basic & Translational Immunology with Prof. Abul Abbas

On Thursday 17th April, a group of us made the journey ‘up the hill’ to the Richard Doll building to attend an immunology masterclass from Professor Abul Abbas. Prof. Abbas is an emeritus professor in Pathology at UCSF and author of numerous core textbooks including Basic Immunology: Functions and Disorders of the Immune System.

The whole-day course consisted of a series of lectures covering core topics in immunology, from innate immunity and antigen presentation through to B/T cell subsets, autoimmunity, and immunotherapy.

Continue reading →

The “AI-ntibody” Competition: benchmarking in silico antibody screening/design

We recently contributed to a communication in Nature Biotechnology detailing an upcoming competition coordinated by Specifica to evaluate the relative performance of in vitro display and in silico methods at identifying target-specific antibody binders and performing downstream antibody candidate optimisation.

Following in the footsteps of tournaments such as the Critical Assessment of Structure Prediction (CASP), which have led to substantial breakthroughs in computational methods for biomolecular structure prediction, the AI-ntibody initiative seeks to establish a periodic benchmarking exercise for in silico antibody discovery/design methods. It should help to identify the most significant breakthroughs in the space and orient future methods’ development.

Continue reading →

Conference Summary: MGMS Adaptive Immune Receptors Meeting 2024

On 5th April 2024, over 60 researchers braved the train strikes and gusty weather to gather at Lady Margaret Hall in Oxford and engage in a day full of scientific talks, posters and discussions on the topic of adaptive immune receptor (AIR) analysis!

Continue reading →

What can you do with the OPIG Immunoinformatics Suite? v3.0

OPIG’s growing immunoinformatics team continues to develop and openly distribute a wide variety of databases and software packages for antibody/nanobody/T-cell receptor analysis. Below is a summary of all the latest updates (follows on from v1.0 and v2.0).

Continue reading →

Experience at a Keystone Symposium

From 19th-22nd February I was fortunate enough to participate in the joint Keystone Symposium on Next-Generation Antibody Therapeutics and Multispecific Immune Cell Engagers, held in Banff, Canada. Now in their 51st year, the Keystone Symposia are a comprehensive programme of scientific conferences spanning the full range of topics relating to human health, from studies on fundamental bodily processes through to drug discovery.

Continue reading →